Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (Adjuvant WIDER)

To look at adding a targeted therapy called ribociclib to standard hormone treatment after surgery for people with early-stage breast cancer that is hormone receptor-positive and HER2-negative. In this study, all participants receive ribociclib along with their usual hormone therapy to help reduce the risk of the cancer coming back, and researchers are evaluating how well this combination works and how safe it is. The goal of the study is to better understand the effectiveness of this treatment approach in women and men with early breast cancer.

• Adults 18+ years of age
• Diagnosed with hormone receptor–positive, HER2-negative early-stage breast cancer
• Has had surgery and has certain higher-risk stage II or III disease
• Can take hormone therapy
• Does not have metastatic disease

• Taking ribociclib by mouth along with standard hormone therapy for up to three years
• Attending regular clinic visits for monitoring, labs, and heart function checks